Targeting CD38 in Subclinical Antibody-mediated Rejection in HLA-incompatible Kidney Transplantation: A Case Report
Open Access
- 18 July 2024
- journal article
- editorial
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (8) , e1685
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammationAmerican Journal of Transplantation, 2023
- The Molecular Phenotype of Kidney Transplants: Insights From the MMDx ProjectTransplantation, 2023
- The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnosticsAmerican Journal of Transplantation, 2023
- Daratumumab for antibody-mediated rejection: Is it time to target the real culprit?American Journal of Transplantation, 2023
- Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodiesFrontiers in Immunology, 2023
- Donor-Specific Antibody Is Associated with Increased Expression of Rejection Transcripts in Renal Transplant Biopsies Classified as No RejectionJournal of the American Society of Nephrology, 2021
- Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working GroupTransplantation, 2020
- CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft RejectionTransplantation, 2020
- Antibody-Mediated Rejection of Solid-Organ AllograftsNew England Journal of Medicine, 2018
- Plasmapheresis and Intravenous Immunoglobulin in Early Antibody‐Mediated Rejection of the Renal Allograft: A Single‐Center ExperienceTherapeutic Apheresis and Dialysis, 2009